Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Evofosfamide (Primary) ; Sorafenib (Primary)
- Indications Liver cancer; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ALLIANCE
- 01 Mar 2021 Results published in the Investigational New Drugs.
- 04 Feb 2020 Status changed from active, no longer recruiting to completed.
- 23 Feb 2018 Status changed from suspended to active, no longer recruiting.